Buy Glucophage SR

Glucophage SR

What is Glucophage SR?

Glucophage SR is a prescription medication that contains Metformin as its active component. Metformin belongs to the biguanide class of antidiabetic agents and is used primarily to improve blood-sugar control in adults with type 2 diabetes mellitus. Glucophage SR is formulated as an extended-release (SR) pill and is marketed in a 500 mg strength. In Hong Kong, the Drug Office of the Department of Health classifies Glucophage SR as a prescription-only drug and requires a qualified healthcare professional’s authorization before it can be dispensed.

How Glucophage SR Works in the Body

Metformin reduces elevated blood glucose through several complementary mechanisms:

• Decreased hepatic glucose production - it inhibits gluconeogenesis (the liver’s creation of new glucose) by activating the enzyme AMP-activated protein kinase (AMPK).
• Improved peripheral insulin sensitivity - muscle and fat cells take up glucose more efficiently, lowering circulating glucose levels.
• Reduced intestinal glucose absorption - a modest portion of the drug limits how much glucose is taken up from the gut after meals.

These actions begin within a few days of therapy, with the full glucose-lowering effect typically evident after 2-3 weeks. Because Metformin is not metabolised by the liver, it is eliminated unchanged by the kidneys, making renal function a key factor in safe dosing.

Conditions Treated by Glucophage SR

Glucophage SR is FDA- and EMA-approved, and consequently approved for use in Hong Kong, for the following indication:

• Type 2 diabetes mellitus in adults, as an adjunct to diet and exercise when lifestyle measures alone do not achieve target glycaemic control.

The medication is intended for patients whose pancreas still produces some insulin, allowing Metformin’s insulin-sensitising effects to be effective. It is not indicated for type 1 diabetes or for treatment of severe hyperglycaemia requiring immediate insulin therapy.

Evidence-Based Off-Label Uses

While Glucophage SR is not formally approved for these conditions, clinical research and practice guidelines have explored additional applications:

• Polycystic ovary syndrome (PCOS) - Metformin can improve ovulatory function and reduce androgen levels in some women with PCOS.
• Gestational diabetes mellitus (GDM) - Metformin is sometimes used when insulin is not feasible, but this remains an off-label choice and requires specialist supervision.

Disclaimer: Off-label use requires medical supervision and an individualized risk-benefit assessment. Patients should discuss any potential off-label therapy with a qualified healthcare provider.

Who Should (Not) Use Glucophage SR?

Absolute Contra-indications

• Known hypersensitivity to Metformin or any of the tablet’s excipients.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²).
• Active metabolic acidosis, including lactic acidosis.
• Severe hepatic disease that predisposes to hypoxia.

Relative Contra-indications

• Moderate renal impairment (eGFR 30-45 mL/min/1.73 m²) - dose reduction and close monitoring are necessary.
• Congestive heart failure (NYHA class III-IV) - careful assessment of renal perfusion.
• Elderly patients - start with the lowest dose and titrate slowly.

Special Populations

• Pregnancy - Metformin may be used when the expected benefit outweighs potential risks; however, insulin remains the first-line agent for most pregnant women with diabetes.
• Breast-feeding - Metformin passes into breast milk in small amounts; many clinicians advise against routine use while nursing.
• Patients on iodinated contrast - Metformin should be temporarily discontinued before and after contrast studies that may impair renal function.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastrointestinal upset - nausea, diarrhoea, abdominal discomfort (often transient and dose-related).
• Metallic taste - reported by a minority of users.
• Loss of appetite - may contribute to modest weight loss.

Serious Adverse Events

• Lactic acidosis - a rare but life-threatening condition characterised by rapid breathing, muscle pain, and altered mental status. Immediate medical attention is required if suspected.
• Vitamin B12 deficiency - long-term Metformin use can reduce B12 absorption; periodic monitoring is advisable.
• Hypoglycaemia - rare when Metformin is used alone, but risk increases when combined with insulin or sulfonylureas.

Drug Interactions

• Cimetidine - can increase Metformin plasma concentrations; dose adjustment may be needed.
• Loop diuretics - may raise the risk of renal dysfunction, indirectly elevating Metformin levels.
• Iodinated contrast agents - can precipitate acute kidney injury; temporarily discontinue Metformin before and after the procedure.
• Alcohol - excessive intake heightens the risk of lactic acidosis.

Food and Lifestyle Interactions

• Meals - take Glucophage SR with the evening meal to minimise gastrointestinal irritation and improve absorption.
• Alcohol - limit consumption; heavy drinking adds lactic acidosis risk.
• Driving or operating machinery - Metformin does not impair cognition, but severe hypoglycaemia (especially when combined with other agents) could affect performance.

How to Take Glucophage SR

• Initial dose: 500 mg taken once daily with the evening meal.
• Titration: The dose may be increased by 500 mg weekly, based on tolerability, to a typical maximum of 2000 mg per day (often split as 1000 mg in the morning and 1000 mg in the evening for the extended-release formulation).
• Renal adjustment: For eGFR 30-45 mL/min/1.73 m², do not exceed 1000 mg per day and monitor renal function every 3-6 months.
• Hepatic considerations: No specific dose change is required, but clinicians should assess liver function before initiation.
• Administration: Swallow the extended-release tablet whole; do not crush, chew, or split, as this may destroy the controlled-release matrix.
• Missed dose: If a dose is missed, take it with the next scheduled meal. Do not double the dose.
• Overdose: Symptoms may include nausea, vomiting, abdominal pain, and lethargy. Prompt emergency care is essential; supportive measures and, if indicated, dialysis are the mainstays of treatment.
• Discontinuation: No taper is required, but abrupt cessation may cause a rebound rise in blood glucose; patients should follow up with a healthcare professional for alternative glycaemic control.

Monitoring and Follow-Up

• Renal function - serum creatinine and eGFR at baseline, then at least annually; more frequent checks if renal impairment is present.
• Glycaemic control - HbA1c every 3-6 months to assess therapeutic response.
• Vitamin B12 - check levels annually in long-term users, especially if neuropathic symptoms appear.
• Liver enzymes - baseline assessment recommended, with repeat testing if clinically indicated.
• Clinical review - patients should report persistent gastrointestinal symptoms, unexplained fatigue, or sudden weight loss, as these may signal adverse effects.

Storage and Handling

• Store tablets at room temperature (15-30 °C), away from excess heat, moisture, and direct sunlight.
• Keep the container tightly closed and out of reach of children and pets.
• Do not use the medication after the printed expiration date.
• Dispose of unused tablets according to local pharmacy-take-back programs or the instructions on the package insert.

Medication-Specific Glossary

Extended-Release (SR)

A formulation designed to release the drug slowly over several hours, allowing once-daily dosing and smoother blood-glucose control.

AMP-activated protein kinase (AMPK)

An enzyme that regulates cellular energy balance; Metformin activates AMPK, leading to reduced hepatic glucose production.

eGFR (estimated Glomerular Filtration Rate)

A calculated measure of kidney filtering capacity; crucial for determining Metformin dosing safety.

Lactic Acidosis

A rare but serious buildup of lactic acid in the blood, potentially fatal if not treated promptly.

Glycated Hemoglobin (HbA1c)

A laboratory test reflecting average blood glucose over the past 2-3 months; used to gauge the effectiveness of diabetes therapy.

Medical Disclaimer

This article provides educational information about Glucophage SR and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.